Panbela Therapeutics Inc

OTCQB:PBLAUnited States

Nov 14, 2024

Show headlines and story abstract

• Panbela Provides Business Update and Reports Q3 2024 Financial Results, from 4:10PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:10PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: PBLA
  
  (In thousands)
  Nine Months Ended September 30, ------------------------------------------ 2024 2023 Cash flows from operating activities: Net loss $ (21,439) $ (18,789) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 103 699 Non-cash interest expense 523 172 Gain on sale of intellectual property (775) (400) Changes in operating assets and liabilities: Income tax receivable (140) (112) Prepaid expenses and other current assets (170) (381) Other non-current assets 4,516 (5,541) Accounts payable 798 4,370 Accrued liabilities 4,091 (2,187) ------------- ------------ Net cash used in operating activities (12,493) (22,169) ============= ============ Cash flows from investing activities: Proceeds from sale of intellectual property 775 400 Net cash provided by investing activities 775 400 ============= ============ Cash flows from financing activities: Proceeds from public offering of common stock and warrants, net of fees and offering costs of $0.9 million and $2.1 million respectively 8,082 23,052 Cash paid for fractional shares - (9) Proceeds from sale of promissory notes 2,200 - Principal payments on notes (1,000) (1,650) ------------- ------------ Net cash provided by financing activities 9,282 21,393 Effect of exchange rate changes on cash - (2) ------------- ------------ Net change in cash (2,436) (378) Cash and cash equivalents at beginning of period 2,578 1,285 ------------- ------------ Cash and cash equivalents at end of period $ 142 $ 907 ============= ============ Supplemental disclosure of cash flow information: Cash paid during period for interest $ 279 $ 398 ============= ============